Syndax Pharmaceuticals (SNDX) Revenue & Revenue Breakdown
Syndax Pharmaceuticals Revenue Highlights
0
Latest Revenue (Q)
$12.50M
Syndax Pharmaceuticals Revenue by Period
Syndax Pharmaceuticals Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | 100.00% |
| 2022-12-31 | - | -100.00% |
| 2021-12-31 | $139.71M | 9109.56% |
| 2020-12-31 | $1.52M | - |
| 2019-12-31 | $1.52M | - |
| 2018-12-31 | $1.52M | -28.04% |
| 2017-12-31 | $2.11M | 72.79% |
| 2016-12-31 | $1.22M | 94.58% |
| 2015-12-31 | $627.00K | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2013-12-31 | - | 100.00% |
| 2012-12-31 | - | - |
Syndax Pharmaceuticals generated - in revenue during NA 2023, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Syndax Pharmaceuticals Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-09-30 | $12.50M | 257.14% |
| 2024-06-30 | $3.50M | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $536.00K | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | -100.00% |
| 2021-12-31 | $126.58M | 922.84% |
| 2021-09-30 | $12.38M | 3165.17% |
| 2021-06-30 | $379.00K | - |
| 2021-03-31 | $379.00K | -0.26% |
| 2020-12-31 | $380.00K | 0.26% |
| 2020-09-30 | $379.00K | - |
| 2020-06-30 | $379.00K | - |
| 2020-03-31 | $379.00K | -0.26% |
| 2019-12-31 | $380.00K | 0.26% |
| 2019-09-30 | $379.00K | - |
| 2019-06-30 | $379.00K | - |
| 2019-03-31 | $379.00K | -0.26% |
| 2018-12-31 | $380.00K | 0.26% |
| 2018-09-30 | $379.00K | - |
| 2018-06-30 | $379.00K | - |
| 2018-03-31 | $379.00K | -68.23% |
| 2017-12-31 | $1.19M | 291.15% |
| 2017-09-30 | $305.00K | - |
| 2017-06-30 | $305.00K | - |
| 2017-03-31 | $305.00K | - |
| 2016-12-31 | $305.00K | - |
| 2016-09-30 | $305.00K | - |
| 2016-06-30 | $305.00K | - |
| 2016-03-31 | $305.00K | - |
| 2015-12-31 | $305.00K | - |
| 2015-09-30 | $305.00K | 1694.12% |
| 2015-06-30 | $17.00K | 100.00% |
| 2015-03-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2014-09-30 | - | 100.00% |
| 2014-06-30 | - | 100.00% |
| 2014-03-31 | - | 100.00% |
| 2013-12-31 | - | 100.00% |
| 2013-09-30 | - | 100.00% |
| 2013-06-30 | - | 100.00% |
| 2013-03-31 | - | - |
Syndax Pharmaceuticals generated $12.50M in revenue during Q3 2024, up 257.14% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Syndax Pharmaceuticals Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| STRO | Sutro Biopharma | $153.73M | $25.71M |
| MRUS | Merus | $43.95M | $11.77M |
| MRSN | Mersana Therapeutics | $36.85M | $12.60M |
| RVMD | Revolution Medicines, Inc. Warrant | $11.58M | - |
| CYTK | Cytokinetics | $7.53M | $463.00K |
| PLRX | Pliant Therapeutics | $1.58M | - |
| KRTX | Karuna Therapeutics | $654.00K | - |
| VRDN | Viridian Therapeutics | $314.00K | $86.00K |
| KROS | Keros Therapeutics | $151.00K | $37.00K |
| CGEM | Cullinan Oncology | - | - |
| PCVX | Vaxcyte | - | - |
| COGT | Cogent Biosciences | - | - |
| AVTE | Aerovate Therapeutics | - | - |
| DICE | DICE Therapeutics | - | - |
| INZY | Inozyme Pharma | - | - |
| DYN | Dyne Therapeutics | - | - |
| REPL | Replimune Group | - | - |
| SNDX | Syndax Pharmaceuticals | - | $12.50M |
| MLYS | Mineralys Therapeutics | - | - |
| LRMR | Larimar Therapeutics | - | - |
| KALV | KalVista Pharmaceuticals | - | - |
| EWTX | Edgewise Therapeutics | - | - |